Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.

[1]  D. Rischin,et al.  Docetaxel effectively mobilizes peripheral blood CD34+ cells , 2000, Bone Marrow Transplantation.

[2]  S. Martino,et al.  Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. , 2000, The New England journal of medicine.

[3]  M. Lippman,et al.  High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer. , 2000, The New England journal of medicine.

[4]  D. Power,et al.  TUBULOINTERSTITIAL NEPHRITIS FOLLOWING HIGH‐DOSE IFOSFAMIDE IN THREE BREAST CANCER PATIENTS , 2000, Pathology.

[5]  R. Negrin,et al.  Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  P. Francis,et al.  Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer , 1999, Bone Marrow Transplantation.

[7]  T. Zimmerman,et al.  A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma , 1998, Cancer.

[8]  I. Bertoncello,et al.  Peripheral blood CD34+ cell count reliably predicts autograft yield , 1998, Bone Marrow Transplantation.

[9]  S. Glück,et al.  A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer. , 1998, European journal of cancer.

[10]  J. Pater,et al.  High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Culine,et al.  Four-step high-dose sequential chemotherapy with hematopoietic progenitor-cell support as induction treatment for patients with solid tumors. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  A. Carella.  Autologous Stem Cell Transplantation: Biological and Clinical Results in Malignancies , 1997 .

[13]  G. Giaccone,et al.  Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  I. Tannock,et al.  Chemotherapy dose escalation: case unproven. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Armitage,et al.  High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Goldschmidt,et al.  Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer. , 1997, European journal of cancer.

[17]  C. Shapiro,et al.  Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Cesne,et al.  Docetaxel and interstitial pulmonary injury. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  B. Overmoyer.  Ifosfamide in the treatment of breast cancer. , 1996, Seminars in oncology.

[20]  S. Rodenhuis,et al.  Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Hanauer,et al.  Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. , 1996, Bone marrow transplantation.

[22]  R. Marcus,et al.  Interstitial pneumonitis as a late complication of high dose therapy with cyclophosphamide/thiotepa and peripheral blood progenitor cell rescue for carcinoma of the breast. , 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).

[23]  L. Seymour,et al.  High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Begley,et al.  Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  G. Sledge,et al.  Progress in chemotherapy for metastatic breast cancer. , 1992, Seminars in oncology.

[26]  J. Fay,et al.  High-dose N,N',N"-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies. , 1990, Seminars in oncology.

[27]  W. Hryniuk,et al.  The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Schulte,et al.  ERGEBNISSE NACH HERZKLAPPENERSATZ MIT STARR-EDWARDS-KUGELPROTHESEN IN AORTEN UND MITRALPOSITION (1962-1976) , 1977 .